Next-Generation Antibody Therapies: World Industry and Market 2014-2024

LONDON, March 5, 2014 /PRNewswire/ --



Antibody technology - discover R&D, business analysis, and revenue forecasts

What's the future of technologies harnessing therapeutic antibodies? Now you can get technological and business predictions. Stay ahead for data, helping your authority. There you explore developmental trends, sales results, opportunities, and revenue forecasts.

Visiongain's new report shows you what's possible for monoclonal antibodies (mAbs) and other immunotechnology for pharmaceuticals. Avoid missing out. Instead find progress in that medical industry and market, discovering the expected progress and gains.

Read on to explore those drugs, seeing how high revenues can go.

Forecasts and other information showing lucrative biopharmaceutical possibilities

The updated study gives you sales predictions to 2024 at overall world, submarket, product, and regional level. For those treatments - antibodies and variants - you investigate where money lies.

Hear what's possible. Also avoid struggles to find information. Besides revenue forecasting, our new work shows historical performance, recent results, growth rates, and market shares. There you also gain feel for developments (R&D) in those medicines.

So discover 74 tables, 58 charts, and three interviews with authorities in that industry, helping your research, analyses, and decisions.

And the following sections explain what our investigation gives you.

Forecasting of that world market and its main segments - what's likely to happen?

What're the secrets of that biomedical industry's progress? Discover in our report overall world revenue to 2024 for those immunological products.

Also find individual revenue predictions to 2024 for five therapeutic submarkets at world level:
• Antibody-drug conjugates (ADCs)
• Engineered antibodies
• Bispecific antibodies
• Antibody fragments and antibody-like proteins (ALPs)
• Biosimilar antibodies (biosimilars).

There you assess outlooks for sales expansion, hearing where you could gain. Our work investigates R&D, competition and rising sales - technological and commercial possibilities.

You explore successes, developments and competition for those biological drugs (biologics). And you find leading therapeutic agents' selling potentials.

To see an exec summary of this report please email Sara Peerun on sara.peerun@visiongainglobal.com

Revenue predictions for top therapeutics in that biotechnological segment

How will individual drugs perform to 2024 at world level? Our study forecasts revenues of six products:
• Adcetris
• Kadcyla
• Poteligeo
• Gazyva
• Removab
• Kalbitor.

And these four biosimilar agents:
• Rituximab
• Infliximab
• Trastuzumab
• Adalimumab.

There you find drugs and years with highest predicted sales. Also you examine competitors. You see what's happening, then, understanding, challenges, trends, and outlooks.

That work also shows geographical revenue predictions.

Healthcare in regional markets - what outlooks for follow-on antibodies?

In developed and developing countries, many opportunities for producers and sellers of next-generation antibody products will occur from 2014 to 2024. See where and how.

Our analyses show you individual revenue forecasts to 2024 for four regional markets:
• United States (US)
• Japan
• European Union (EU)
• Rest of world (grouped).

There you find countries with highest revenues, demand, and potential sales growth. Explore progress, needs and opportunities.

What events, challenges and expectations affect that industry and market? Our work shows you, discussing events, policies, and trends influencing that pharma field.

Forces affecting developers, producers, and sellers of those immunotechnological agents

The report explains issues and events affecting that industry and market from 2014, including these:
• Improved monoclonal antibodies, Fab fragments, and receptor constructs
• Drug approvals and outlooks
• Acquisitions by big pharmaceutical companies
• R&D pipelines for new therapies - e.g. CD19, CD20, and HER targeting - including biosuperiors
• Cancer treatments - ovarian, breast, prostate, lymphoma, and leukaemia.

And you explore these influences, among others:
• Modifying amino acids in the Fc domain
• Recombinant antibody mixtures - improving therapeutic proteins
• Single-chain variable fragment platforms
• Product lifecycle management and regulatory affairs
• Contract manufacturing organisations (CMOs) investing in next-generation antibody technologies.

See too how R&D lets companies benefit patients. You find what stimulates and restrains players in that sector, and affects its results.

To see an exec summary of this report please email Sara Peerun on sara.peerun@visiongainglobal.com

New antibody technology and applications - companies and 2018 market value

From 2014, novel treatments and demands from patients, doctors, and payers encourage investments, medical advances, and higher revenues from immune-based technologies.

And what happens next? Our study predicts that world market will reach $6.7bn in 2018.

There you examine activities of many companies, including these:
• Roche
• Pfizer
• Seattle Genetics
• Amgen
• Kyowa Hakko Kirin
• ImmunoGen.

You find 180 organisations covered. You also get three interviews with leaders in that industry. Discover what participants do, say, and think, helping you stay ahead.

Ways Next-Generation Antibody Therapies: World Industry and Market 2014-2024  helps

Through knowledge such as this, our new report helps you gain recognition for insight:
• Revenues there to 2024 at world level, for 5 submarkets, and 10 products - assess outlooks for production, marketing, and sales
• Forecasts to 2024 for four regional markets - investigate leading regions and countries for revenues and sales expansion
• Prospects for established competitors, rising companies, and new entrants - explore portfolios, results, strategies, R&D, and outlooks for success.

Information found nowhere else, helping your searches, analyses, and planning

Our study gives independent analysis. There you receive competitive intelligence found only in our work, finding where money and progress lie. You explore the business possibilities.

With that data you're less likely to fall behind in knowledge or miss opportunity. Being free to choose, you find with our report how you could save time and effort. And also help your plans, decisions, influence, and competing.

Our new report is for everyone analysing medical biotechnology. There you explore crucial trends, finding sales potentials from 2014. So avoid missing out - please order now.

To request an exec summary of this report please email Sara Peerun at sara.peerun@visiongainglobal.com or call Tel: +44(0)20-7336-6100

Or click on http://www.visiongain.com/Report/1210/Next-Generation-Antibody-Therapies-World-Industry-and-Market-2014-2024

Companies Listed in this report:

AbbVie
Abgenix (part of Amgen)
Ablynx
Actavis
ADC Therapeutics
Adnexus (part of Bristol-Myers Squibb)
AET BioTech
Affibody
Affimed Therapeutics
Agensys (part of Astellas Pharma)
Alcon (part of Novartis)
Alexion Pharmaceuticals
Allergan
Allozyne
Ambrx
Amgen
AMRI
Aprogen
Arana Therapeutics (part of Cephalon)
Astellas Pharma
AstraZeneca
Auven Therapeutics
Bayer Healthcare
Biocad
Bioceros
Biocon
Biogen Idec
Biotest
BioWa (part of Kyowa Hakko Kirin)
BioXpress Therapeutics
Boehringer Ingelheim
Bristol-Myers Squibb
BZL Biologics
Catalent Pharma Solutions
Celgene
Celldex Therapeutics
Celltech (part of UCB)
Celltrion
Cephalon (part of Teva)
CinnaGen
Comisión Federal para la Protección contra Riesgos Sanitarios (Cofepris) [Mexico]
Concortis Biosystems (part of Sorrento Therapeutics)
Corixa
Covagen
Crescendo Biologics
CVie Therapeutics
CytomX Therapeutics
Daiichi Sankyo
Defiante Farmaceutica (part of Sigma-Tau)
Delenex Therapeutics
Dendreon
Domantis (part of GSK)
Dong-A Pharmaceutical
Dr. Reddy's Laboratories
Drug Controller General of India (DCGI)
Dyax
Eddingpharm
Egis Pharmaceuticals
Elan Pharmaceuticals
Eli Lilly
Epirus Biopharmaceuticals
ESBATech (part of Novartis)
ETH Zurich
European Medicines Agency (EMA)
EvaluatePharma (now Evaluate)
F-star
Five Prime Therapeutics
Food and Drug Administration (FDA) [US]
Fresenius Biotech (now named Neovii Biotech, part of Neopharm)
Fresenius Group
Fujifilm
Fujifilm Diosynth Biotechnologies
Fujifilm Kyowa Kirin Biologics
GE Healthcare
Gedeon Richter
Genentech (part of Roche)
Genmab
Gilead Sciences
GlycoExpress
Glycotope
GSK
Hanwha Chemical
Helmholtz Zentrum München
Hospira
IBC Pharmaceuticals (part of Immunomedics)
Igenica
Immunocore
ImmunoGen
Immunomedics
Intas Biopharmaceuticals
Isu Abxis
J&J
Janssen Biotech (part of J&J)
Janssen-Cilag (part of J&J)
KaloBios
Karolinska Institute
Kyowa Hakko Kirin
Kyowa Medex (part of Kyowa Hakko Kirin)
Laboratoires Français de Fractionnement et des Biotechnologies (LFB)
LFB Biomanufacturing (part of LFB)
Life Science Pharmaceuticals
LINDIS Biotech
LMC
Lonza
Mabion
MacroGenics
MedImmune (part of AstraZeneca)
Mentrik Biotech
Merck & Co.
Merck Serono
Merrimack Pharmaceuticals
Mersana Therapeutics
Merus Biopharmaceuticals
Micromet (part of Amgen)
Millennium Pharmaceuticals (part of Takeda)
Ministry of Food and Drug Safety (MFDS) [South Korea]
Ministry of Health [Brazil]
Ministry of Health, Labor and Welfare (MHLW) [Japan]
Mitsubishi Tanabe Pharma
Molecular Partners
MorphoSys
Mylan
National Health Service (NHS) [UK]
National Institute for Health and Care Excellence (NICE) [UK]
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Nektar Therapeutics
Neopharm Group
Nichi-Iko Pharmaceutical
Novartis
Novellus Biopharma
Orygen Biotecnologia
Oxford BioMedica
Oxford BioTherapeutics
Pfizer
Pharmacyclics
PharmaPraxis
Pieris
Piramal Group
PlantForm
Probiomed
Progenics Pharmaceuticals
ProStrakan Group (part of Kyowa Hakko Kirin)
Ranbaxy Laboratories (part of Daiichi Sankyo)
Redwood Bioscience
Regeneron Pharmaceuticals
Reliance GeneMedix (part of Reliance Life Sciences)
Reliance Life Sciences
Roche
Roche Glycart (part of Roche)
Royal Institute of Technology (KTH) [Sweden]
SAFC
Samsung Bioepis
Samsung BioLogics
Sandoz (part of Novartis)
Sanofi
Scil Proteins
Seattle Genetics
Servier
Shanghai CP Guojian
Sigma-Tau Pharmaceuticals
Sorrento Therapeutics
Sothema Laboratories
Spectrum Pharmaceuticals
Spirogen (part of AstraZeneca)
Stada
Stelis Biopharmaceuticals (part of Strides Arcolab)
Strides Arcolab
Sutro Biopharma
Swedish Orphan Biovitrum (Sobi)
Swiss Federal Institute of Technology
Symphogen
Synthon
Synthon Biopharmaceuticals (part of Synthon)
Takeda Pharmaceutical Company
Talon Therapeutics (part of Spectrum Pharmaceuticals)
Targa Therapeutics
Teva Pharmaceutical Industries
TG Therapeutics
TRION Pharma
UCB
US Patent and Trademark Office
World Health Organization (WHO)
Wyeth (part of Pfizer)
Xencor
Zydus Cadila

To see an exec summary of this report please email Sara Peerun on sara.peerun@visiongainglobal.com